Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT01105390
Other study ID # E1B09
Secondary ID NCI-2011-02068U1
Status Withdrawn
Phase Phase 2
First received April 15, 2010
Last updated August 1, 2013
Start date April 2010

Study information

Verified date January 2013
Source National Cancer Institute (NCI)
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review BoardUnited States: Federal Government
Study type Interventional

Clinical Trial Summary

This phase II trial is studying how well giving AMG 102 together with pemetrexed disodium and cisplatin works in treating patients with malignant pleural mesothelioma. Monoclonal antibodies, such as AMG 102, can block tumor growth in different ways. Some block the ability of tumor cells to grow or spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as pemetrexed disodium and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving AMG 102 together with pemetrexed disodium and cisplatin may kill more tumor cells


Description:

PRIMARY OBJECTIVES:

I. To evaluate the progression-free survival of patients with malignant pleural mesothelioma (MPM) treated with anti-HGF monoclonal antibody AMG 102 in combination with pemetrexed disodium and cisplatin.

SECONDARY OBJECTIVES:

I. To assess the toxicity associated with this regimen in these patients. II. To determine the response rate of patients treated with this regimen. III. To determine the overall survival of patients treated with this regimen. IV. To evaluate multiple potential correlative biomarkers in MPM that are relevant to this combined regimen, including serum HGF and mesothelin levels, c-met expression by IHC in tumor specimens, presence of c-met mutations in tumor, and the presence of thymidylate synthetase (TS) and excision repair cross complementing protein-1 (ERCC1) polymorphisms.

OUTLINE: This is a multicenter study.

Patients receive anti-HGF monoclonal antibody AMG 102 (AMG 102) IV over 1 hour, pemetrexed disodium IV over 10 minutes, and cisplatin IV over 1 hour on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients without disease progression may continue AMG 102 IV over 1 hour on day 1, every 3 weeks, as maintenance therapy in the absence of disease progression. Some patients undergo blood sample collection at baseline and periodically during study for correlative biomarker studies. Tumor samples from diagnostic tissue may also be analyzed.

After completion of study therapy, patients are followed up periodically every 3 months for 2 years and then every 6 months for 1 year.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date
Est. primary completion date May 2011
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Histologically and cytologically confirmed malignant mesothelioma of the pleura

- All subtypes allowed

- Disease not amenable to curative surgery

- Measurable disease

- Patients with disease not measurable by standard RECIST criteria (i.e., pleural rinds/thickening only) allowed

- Pleural effusions or positive bone scans are not considered measurable

- No prior radiotherapy to the target lesion or measurable lesion unless the site has subsequent evidence of progression

- Patients who have undergone pleurodesis allowed

- Post-pleurodesis CT scan required

- No known or suspected brain metastases

- ECOG performance status 0-1

- ANC = 1,500/mm^3

- Platelet count = 100,000/mm^3

- Total bilirubin = 1.5 times upper limit of normal (ULN)

- Alkaline phosphatase = 1.5 times ULN

- ALT and AST = 1.5 times ULN

- Albumin = 2.5 g/dL

- Creatinine clearance = 45 mL/min OR serum creatinine = 1.5 times ULN

- Able to take folic acid and vitamin B12

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must agree to use effective contraception

- No active infection or serious concomitant systemic disorder in compatible with the study

- No thrombosis or vascular ischemic events within the last 12 months, including any of the following:

- Deep venous thrombosis

- Pulmonary embolism

- Transient ischemic attack

- Cerebral infarction

- Myocardial infarction

- No peripheral edema = grade 3

- No serious or non-healing wounds

- No second primary malignancy except in situ carcinoma of the cervix or breast, other in situ malignancies, adequately treated basal cell carcinoma of the skin, or other malignancy within the past 3 years with no evidence of recurrence

- No concurrent antiretroviral therapy for HIV-positive patients

- At least 4 weeks since prior radiotherapy

- More than 30 days since major surgery procedures or > 14 days since any minor surgical procedure and recovered

- Central venous catheter placement, fine-needle aspiration, thoracentesis, or paracentesis are not considered major or minor surgical procedures

- No prior systemic chemotherapy for mesothelioma

- No prior intracavity cytotoxic drugs or immunomodulators (unless for the purpose of pleurodesis)

- No prior anti-HGF monoclonal antibody AMG 102, other c-MET, or HGF inhibitors

- No prior or concurrent anticoagulation therapy within the past 7 days

- Low-dose Coumadin-type anticoagulants or low-molecular weight heparin for prophylaxis against central venous catheter thrombosis allowed

- No investigational agents within the past 4 weeks

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Biological:
rilotumumab
Given IV
Drug:
cisplatin
Given IV
pemetrexed disodium
Given IV
Other:
laboratory biomarker analysis
Correlative studies

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
National Cancer Institute (NCI)

Outcome

Type Measure Description Time frame Safety issue
Primary Progression-free survival From registration to clinical evidence of disease progression or death without progression, assessed up to 3 years No
Secondary Toxicity defined as a grade 4 hemorrhagic event or a grade 5 event Graded using the NCI CTCAE. Up to 30 days after completion of study treatment Yes
See also
  Status Clinical Trial Phase
Completed NCT00025207 - Gefitinib in Treating Patients With Malignant Mesothelioma Phase 2
Completed NCT00107432 - Sorafenib Tosylate in Treating Patients With Malignant Mesothelioma. Phase 2
Terminated NCT00028782 - EF5 in Detecting Oxygen Level and Blood Vessels in Tumor Cells of Patients Undergoing Photodynamic Therapy for Intraperitoneal or Pleural Cancer N/A
Completed NCT00027703 - Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma Phase 2
Recruiting NCT04213794 - Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric Patients Early Phase 1
Completed NCT01503177 - Intrapleural Measles Virus Therapy in Patients With Malignant Pleural Mesothelioma Phase 1
Completed NCT00243074 - S0509 - AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery Phase 2
Completed NCT01126346 - Quality of Life and Survivorship Care in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy (HIPEC) N/A
Completed NCT00039182 - Erlotinib in Treating Patients With Malignant Mesothelioma of the Lung Phase 2
Withdrawn NCT01325753 - Cryotherapy in Treating Patients With Lung Cancer That Has Spread to the Other Lung or Parts of the Body N/A
Completed NCT00459862 - Pazopanib in Treating Patients With Malignant Pleural Mesothelioma Phase 2
Active, not recruiting NCT01064648 - Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma Phase 1/Phase 2
Completed NCT00365053 - PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery Phase 2
Terminated NCT01861301 - Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma Phase 2
Completed NCT00392444 - Sunitinib in Treating Patients With Advanced Malignant Pleural Mesothelioma Phase 2
Completed NCT00309946 - Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery Phase 2
Completed NCT00030498 - Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction Phase 1
Recruiting NCT03420963 - Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors Phase 1